1 / 32

Personalized cancer therapy

Personalized cancer therapy. Rasoul Salehi r_salehi@med.mui.ac.ir. Personalized therapy. Personalized cancer medicine is based on increased knowledge of the cancer mutations and availability of agents that target altered genes or pathways. Personalized cancer therapy. GENOMIC MEDICINE.

ceana
Download Presentation

Personalized cancer therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Personalized cancer therapy RasoulSalehi r_salehi@med.mui.ac.ir

  2. Personalized therapy • Personalized cancer medicine is based on increased knowledge of the cancer mutations and availability of agents that target altered genes or pathways.

  3. Personalized cancer therapy

  4. GENOMIC MEDICINE • Is the use of information from genomes and their derivatives (RNA, proteins, and metabolites) to guide medical decision making. • It is a key component of personalized medicine

  5. BENEFIT – TOXICITES/RATIO

  6. Colorectal cancer genetic testing

  7. Cell signalling pathways in colorectal cancer

  8. Operational Wnt signaling pathway

  9. KRAS mutations (which occur in approximately 45–50% of patients with CRC) is now routine clinical practice and anti-EGFR treatment is only given to patients who are KRAS wild type. This is the first true use of personalized medicine in CRC.

  10. Activation of Ras following ligandbinding to receptor tyrosine kinases (RTKs).

  11. Kinase cascade that transmits signals downstream fromactivated Ras protein to MAP kinase

  12. UGT1A1 polymorphism • UDP-glucuronosyltransferase1-1 also known as UGT-1A is an enzyme encoded by the humanUGT1A1 gene • UGT-1A is a UDP-glucuronosyltransferase, (UDPGT), an enzyme that transforms small lipophilic molecules, such as steroids, bilirubin, hormones and drugs into water-soluble, excretabl metabolites

  13. UGT1A1 genotyping and irinotecan (IRI) toxicity in advanced CRC cases • Prospective analysis of UGT1A1 genotyping for predicting toxicities in advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens: Interim safety analysis of a Japanese observational study. • Conclusions: Considering UGT1A1 genotype along with other clinical factors is important for managing pts undergoing IRI-based regimens. Our presentation will provide analysis of data from more than 1000 pts

  14. DPYD mutation analysis • 5-fluorouracil (5-FU) is a fluoropyrimidine drug and is the most frequently used chemotherapeutic drug in the treatment of colorectal cancer and other solid tumors. • The dihydropryrimidinedehydrogenase (DPD) enzyme, encoded by theDPYD gene, is responsible for the degradation and inactivation of greater than 80 percent of 5-FU.

  15. DPYD mutation analysis • Reduced DPD activity can lead to the accumulation of active 5-FU metabolite (FdUMP), which leads to 5-FU sensitivity. The consequences of increased sensitivity could be increased efficacy and/or severe dose-related toxicity. • DPYD mutations are associated with decreased DPD activity, leading to production of proportionately higher than normal amounts of FdUMP and increased risk for dose-related 5-FU sensitivity.

  16. Methylenetetrahydrofolatereductase (MTHFR) polymorphism • MTHFR is involved in the metabolism of folate and forms the reduced folate cofactor needed for TS (thymidylatesynthase) inhibition. • Mutations in the MTHFR gene lead to reduced MTHFR enzyme activity, which increases intracellular folate metabolites and may increase the rate of activity of TS.

  17. Methylenetetrahydrofolatereductase (MTHFR) polymorphism • The primary target for 5-FU is TS, encoded by the TYMS gene. • TS catalyses the methylation of deoxyuridinemonophosphate (dUMP) to deoxythymidinemonophsophate (dTMP), which is essential for DNA replication. • An active metabolite of 5-FU, fluorodeoxyuridinemonophosphate (5-FdUMP) prevents DNA synthesis by forming stable complexes with TS with folate as a co-factor, thus preferentially blocking the production of dTMP in cancer cells.

  18. ERCC1, XRCC1, GSTP1 polymorphisms • excision repair cross-complementation 1 & 2 (ERCC1 & 2) , X-ray cross-complementing 1 (XRCC1), genotypes are independently associated with poor progression-free survival and short-term survival • Glutathione S-transferase P1 (GSTP1) is a subclass of Glutathione S-transferases (GSTs) that directly participates in the detoxification of platinum compounds and is an important mediator of both intrinsic and acquired resistance to platinum

  19. platinum complexes react in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis.

  20. Lynch syndrome or HNPCC • MSI & IHC testing

  21. Human MMR Genes MLH1 (3p21) MSH2 (2p16) PMS2 (7p22) MSH6 (2p16) PMS1 (2q31-33) MSH3 (5q3)

  22. MSI TESTING MSI is detected by comparing PCR amplicons of the microsatellite loci . Unstable loci appear as extra products in tumor tissue compared to normal tissue.

  23. Prognosis – Several studies have shown that MSI tumors have a more favorable prognosis and are less prone to lymph node and systemic metastasis. • Prediction of response to 5-FU and irinotecan therapy – Current data suggests that stage II MSI tumors do not benefit (and might actually be harmed) by 5-FU therapy and MSI tumors may be more responsive to irinotecan than microsatellite stable (MSS) tumors. • Detection of Lynch Syndrome - The role of MSI as a genetic marker of Lynch Syndrome is well established. Both MSI detection and IHC are highly sensitive methods for the identification of a defective MMR system and guide clinicians towards informative, cost-effective genetic testing.

  24. Hereditary cancer prevalence control • Positive family history • Appropriate genetic testing • Family members screening, based on information obtained from index case genetic testing • PGD could be provided to those who are inherited the mutation • Healthy, disease free offsprings resulting in gradual eradication of hereditary cancers

  25. Thanks for your kind attendance and attention

More Related